For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...
2h
ScienceAlert on MSNNew Protein Discovery Could Rival Ozempic With Fewer Side EffectsScientists have discovered a naturally-occurring molecule that aids appetite control and weight loss so well, it may compete ...
11h
Avocadu on MSNMicrodosing GLP-1s: A New Approach to Weight Loss and Metabolic HealthIf you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...
1d
News Medical on MSNGLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patientsResearchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...
GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.
3d
HealthDay on MSNNo Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration PneumoniaPreoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...
8d
News Medical on MSNNew study confirms GLP-1 medications are safe for mental health in diabetesResearchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results